Mitsuma Ayako, Ito Yasuki, Shimokata Tomoya, Tanaka Chie, Uehara Kay, Nakayama Goro, Terasaki Hiroko, Ando Yuichi
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Department of Ophthalmology, Nagoya University Hospital, Nagoya, Japan.
Cancer Diagn Progn. 2022 May 3;2(3):330-335. doi: 10.21873/cdp.10113. eCollection 2022 May-Jun.
BACKGROUND/AIM: Antiangiogenic chemotherapy is the backbone of the various anticancer therapies. To date no practical biomarker predicting their antitumor effects and toxicity has been reported. We aimed to determine the feasibility of direct retinal observation as a practical biomarker in antiangiogenic chemotherapy.
By direct retinal observation using a nonmydriatic retinal camera, we measured retinal microvessel diameters in 10 patients with colorectal cancer before and after intravenous infusion of bevacizumab and oxaliplatin. All patients also received oral capecitabine during their therapy.
Retinal microvessel diameters were decreased from baseline temporarily by 14.5±6.5% after infusion of bevacizumab and oxaliplatin in five patients who responded to treatment and 8.8±6.2% in the other five patients (p=0.008).
Measurement of retinal microvessel diameters by direct observation appears to be feasible in patients receiving systemic chemotherapy. The decrease of retinal microvessel diameters might indicate improved tumor response to treatment with bevacizumab-containing systemic chemotherapy.
背景/目的：抗血管生成化疗是各种抗癌治疗的核心。迄今为止，尚未有可预测其抗肿瘤效果和毒性的实用生物标志物的报道。我们旨在确定直接视网膜观察作为抗血管生成化疗实用生物标志物的可行性。
通过使用免散瞳视网膜相机进行直接视网膜观察，我们测量了10例结直肠癌患者静脉输注贝伐单抗和奥沙利铂前后的视网膜微血管直径。所有患者在治疗期间还接受了口服卡培他滨。
在5例对治疗有反应的患者中，输注贝伐单抗和奥沙利铂后，视网膜微血管直径较基线暂时降低了14.5±6.5%，在另外5例患者中降低了8.8±6.2%（p=0.008）。
对于接受全身化疗的患者，通过直接观察测量视网膜微血管直径似乎是可行的。视网膜微血管直径的减小可能表明含贝伐单抗的全身化疗对肿瘤的治疗反应有所改善。
